Shuttle Pharmaceuticals Files 8-K: Agreements, Personnel Changes

Ticker: SHPH · Form: 8-K · Filed: Mar 31, 2025 · CIK: 1757499

Shuttle Pharmaceuticals Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyShuttle Pharmaceuticals Holdings, Inc. (SHPH)
Form Type8-K
Filed DateMar 31, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, personnel-change, corporate-action

TL;DR

Shuttle Pharma 8-K: Material agreement signed, exec/director changes, financial updates filed.

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on March 30, 2025, reporting the entry into a material definitive agreement, the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions at Shuttle Pharmaceuticals, including material agreements and changes in leadership, which could impact the company's strategic direction and operations.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and changes in directors/officers, which can introduce uncertainty and potential shifts in company strategy.

Key Players & Entities

  • Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
  • March 30, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 001-41488 (filing_id) — SEC File Number
  • 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (address) — Principal executive offices

FAQ

What specific material definitive agreement was entered into by Shuttle Pharmaceuticals?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.

Who are the directors or officers that have departed from Shuttle Pharmaceuticals?

The filing mentions the departure of directors or certain officers, but their names are not specified in the provided text.

Who has been elected as a director or appointed as an officer at Shuttle Pharmaceuticals?

The filing states the election of directors and appointment of certain officers, but their identities are not detailed in the provided text.

What is the nature of the compensatory arrangements mentioned in the filing?

The filing refers to compensatory arrangements of certain officers, but the specifics of these arrangements are not elaborated upon in the provided text.

What financial statements and exhibits are included with this 8-K filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the content of these statements and exhibits is not detailed in the provided text.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 31, 2025 regarding Shuttle Pharmaceuticals Holdings, Inc. (SHPH).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.